Comparison of the Non-rebreather Mask With the Double-trunk Mask

Sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain (Other)
Overall Status
Completed
CT.gov ID
NCT04383821
Collaborator
(none)
25
3
2
13.5
8.3
0.6

Study Details

Study Description

Brief Summary

This study will compare the impact of the Double-Trunk Mask (DTM) with the Non-Rebreather Mask (NRM) on the blood gases of patients with severe hypoxemia.

Condition or Disease Intervention/Treatment Phase
  • Device: Double-Trunk Mask
  • Device: Non-Rebreather mask
N/A

Detailed Description

The Double-Trunk Mask (DTM) is a device designed to increase the fraction of inspired oxygen in patients who receive oxygen therapy. The mask is composed of a regular aerosol mask with corrugated tubing (15 cm length) inserted into two lateral holes.

Each included patient will wear the standard Non-Rebreather Mask (NRM) which is the standard delivery oxygen system for patients with acute severe hypoxemia. Then the patients will wear the DTM for 30 minutes. Finally the DTM will be replaced by the NRM for the next 30 minutes. The impact of both oxygen delivery system will be assessed by measuring the change of blood gases with each system.

Study Design

Study Type:
Interventional
Actual Enrollment :
25 participants
Allocation:
Non-Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Comparison of the Effects of Two Oxygen Delivery Systems on Arterial Blood Gases: Non-rebreather Mask Versus Double-trunk Mask
Actual Study Start Date :
May 15, 2020
Actual Primary Completion Date :
Jul 1, 2021
Actual Study Completion Date :
Jul 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Double-Trunk Mask

The oxygen delivery system is the DTM

Device: Double-Trunk Mask
The DTM (oxygen delivery system) is worn by the patient for 30 minutes.

Active Comparator: Non-Rebreather Mask

The oxygen delivery system is the NRM

Device: Non-Rebreather mask
The NRM (standard oxygen delivery system) is worn by the patient for 30 minutes.

Outcome Measures

Primary Outcome Measures

  1. Changes in PaO2 [At baseline and 30 minutes after wearing DTM]

    Oxygen tension (PaO2) in mmHg will be analyzed from a sample taken from the arterial system

Secondary Outcome Measures

  1. Changes in PaCO2 [At baseline and 30 minutes after wearing DTM]

    Carbon dioxide tension (PaCO2) in mmHg will be analyzed from a sample taken from the arterial system

  2. Changes in pH [At baseline and 30 minutes after wearing DTM]

    Potential of Hydrogen (pH) will be analyzed from a sample taken from the arterial system.

  3. Changes in respiratory rate [At baseline and 30 minutes after wearing both systems]

    Respiratory rate is measured during one minute by visual inspection.

  4. Comfort with the oxygen delivery systems [30 minutes after wearing both systems]

    A Likert scale from -5 to +5 will be used to measure the subjective comfort of the patient while wearing both oxygen delivery systems

  5. Dyspnea with the oxygen delivery systems [30 minutes after wearing both systems]

    A Visual Analogic Scale 0 to 10 will be used to measure the dyspnea of the patient while wearing both oxygen delivery systems

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

• Acute hypoxemia not corrected with nasal cannula

Exclusion Criteria:
  • Chronic obstructive pulmonary disease or other chronic respiratory disease with hypercapnia

  • Confusion

  • Contra-indications to arterial blood gas sampling (peripheral arteriopathy, bleeding disorder)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cliniques universitaires Saint-Luc Brussels Brussels Capital Belgium 1200
2 Epicura Hornu Belgium
3 Centre Hospitalier Universitaire de Tivoli La Louvière Belgium

Sponsors and Collaborators

  • Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
William Poncin, PT, PhD, Principal Investigator, Cliniques universitaires Saint-Luc- Université Catholique de Louvain
ClinicalTrials.gov Identifier:
NCT04383821
Other Study ID Numbers:
  • DTM-002
First Posted:
May 12, 2020
Last Update Posted:
Feb 8, 2022
Last Verified:
Feb 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 8, 2022